Epidemiologic trends, occurrence of extended-spectrum β-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002-2007 from the SMART study

Surgical Infections

Volumn 11, Issue 4, 2010, Pages 371-378

  Hawser, Stephen P ^a   Bouchillon, Samuel K ^b   Hoban, Daryl J ^b   Badal, Robert E ^b  

^a International Health Management Associates Europe Sàrl   (Switzerland)

^b Division of Microbiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; AFRICA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIUM ISOLATE; CITROBACTER FREUNDII; DRUG EFFICACY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENZYME SYNTHESIS; ESCHERICHIA COLI; EUROPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS; HOSPITAL PATIENT; HUMAN; INTESTINE INFECTION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MIDDLE EAST; MORGANELLA MORGANII; NONHUMAN; NORTH AMERICA; OUTPATIENT; PACIFIC OCEAN; PERITONITIS; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; SOUTH AND CENTRAL AMERICA; STENOTROPHOMONAS MALTOPHILIA;

AFRICA; ANIMALS; ANTI-BACTERIAL AGENTS; ASIA; AUSTRALASIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; EUROPE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LATIN AMERICA; MIDDLE EAST; NORTH AMERICA; PERITONITIS;

EID: 77955649358     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2009.057     Document Type: Article

References (26)

1. Bochicchio GV, Baquero F, Hsueh PR, et al. In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: Results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Surg Infect 2006;7:537-545.
2. Rossi F, Baquero F, Hsueh P-R, et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006;58:205-210.
3. Diekema DJ, Pfaller MA, Turnidge J, et al. Genetic related- ness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY antimicrobial resistance surveillance centers worldwide, 1998. Microb Drug Resist 2000;6:213-221.
4. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-973.
5. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Thirteenth Information Supplement M100-S18. Clinical Laboratory Standards Institute. Villanova, PA. 2008.
6. Stone ND, O'Hara CM, Williams PP, et al. Comparison of disk diffusion, VITEK 2, and broth microdilution antimicrobial susceptibility test results for unusual species of En- terobacteriaceae. J Clin Microbiol 2007;45:340-346.
7. Lockhart SR, Abramson MA, Beekmann SE, et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care units in the United States between 1993 and 2004. J Clin Microbiol 2007; 45:3352-3359.
8. Baquero F, Hsueh P-R, Paterson DL, et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram- negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Surg Infect 2009;10:99-104.
9. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase and AmpC-producing Enterobacteriaceae from the MYSTIC program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005;53:257-264.
10. Hirakata Y, Matsuda J, Miyazaki Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase- producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis 2005;52:323-329.
11. Sader HS, Hsiung A, Fritsche TR, et al. Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. Diagn Microbiol Infect Dis 2007;57:341-344.
12. Chow JW, Satishchandran V, Snyder TA, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect 2006;6:439-447.
13. Bissett L. ESBL-producing Enterobacteriaceae: Controlling the spread of infection. Br J Nursing 2007;16:644-647.
14. Bush K. Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infection 2008;14:134-143.
15. Canton R, Novais A, Valverde A, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing En- terobacteriaceae in Europe. Clin Microbiol Infect 2008;14: 21-24.
16. Nicolas-Chanoine MH, Jarlier V. Extended-spectrum beta- lactamases in long-term-care facilities. Clin Microbiol Infection 2007;14:111-116.
17. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase- producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect Dis 2008;8:159-166.
18. Bukholm G, Tannaes T, Kjelsberg AB, Smith-Erichsen N. An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect Control Hosp Epidemiol 2002;23:441-446.
19. Dorsey G, Borneo HT, Sun SJ, et al. A heterogeneous outbreak of Enterobacter cloacae and Serratia marcescens infections in a surgical intensive care unit. Infect Control Hosp Epidemiol 2002;21:465-469.
20. Gastmeier P, Groneberg K, Weist K, Ruden H. A cluster of nosocomial Klebsiella pneumoniae bloodstream infections in a neonatal intensive care department: Identification of transmission and intervention. Am J Infect Control 2003;31: 424-430.
21. Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-215.
22. Monnet DL, Archibald LK, Phillips L, et al. Antimicrobial use and resistance in eight U.S. hospitals: Complexities of analysis and modeling. Intensive Care Antimicrobial Resistance Epidemiology Project and National Nosocomial Infections Surveillance System Hospitals. Infect Control Hosp Epidemiol 1998;19:388-394.
23. National Nosocomial Infections Surveillance System. NNIS Report: Data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-498.
24. Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41:363-373.
25. Bonten MJ, Weinstein RA. The role of colonization in the pathogenesis of nosocomial infections. Infect Control Hosp Epidemiol 1996;17:193-200.
26. Margreet P, Filius G, Gyssens IC, et al. Colonization and resistance dynamics of gram-negative bacteria in patients during and after hospitalization. Antimicrob Agents Che- mother 2005;49:2879-2886.